Lonza Group AG

Lonza Group AG maintains a capital structure characterized by significant leverage relative to equity, with a debt-to-equity ratio of 0.57 and long-term debt totaling CHF 4.54 billion against total equity of CHF 7.91 billion. The balance sheet shows total assets of CHF 17.91 billion and total liabilities of CHF 9.99 billion. Liquidity is assessed as medium risk, supported by a current ratio of 1.89, which indicates adequate short-term asset coverage for liabilities. However, the company holds only CHF 481 million in cash and equivalents, resulting in a negative net cash position when total debt is subtracted. This structural deficit is highlighted in risk assessments as a key flag, noting that net cash is negative after subtracting total debt.

Profitability metrics reflect a period of financial strain, with the company reporting a net income loss of CHF 275 million on revenues of CHF 6.53 billion. This results in a negative return on equity of -3.48% and a negative return on assets of -1.54%. Despite the net loss, the company generated an operating income of CHF 1.24 billion and a gross profit of CHF 3.59 billion, indicating that core operational margins remain positive but are being eroded by non-operating expenses or significant one-time charges. The valuation multiples reflect this earnings pressure, with an EV/EBITDA of 57.38 and an EV/Revenue of 10.89, suggesting the market is pricing in future recovery or strategic value beyond current earnings. The price-to-book ratio stands at 8.47, indicating a substantial premium over tangible book value.

Revenue generation is driven by the company's core CDMO activities, though specific segment breakdowns are not detailed in the provided snapshot. The geographic exposure and customer concentration risks are not explicitly quantified in the available data, but the nature of the pharmaceutical services industry typically involves high concentration among large biopharmaceutical clients. The company's activity is centered on the development and manufacturing of complex therapies, which requires significant capital investment and long-term client relationships.

The growth trajectory is obscured by the lack of historical period data in the current snapshot, but the current revenue base of CHF 6.53 billion provides a scale for analysis. The negative net income contrasts with positive operating cash flow of CHF 1.16 billion, suggesting that the losses are driven by non-cash items such as impairments or stock-based compensation rather than operational cash burn. Free cash flow is minimal at CHF 64 million, heavily impacted by capital expenditures of CHF 1.38 billion, which underscores the capital-intensive nature of the business and the ongoing investment in manufacturing capacity.

Risk factors include medium liquidity risk and medium dilution risk. The negative net cash position creates refinancing risk, particularly in a higher interest rate environment. Dilution risk is flagged due to source documents mentioning offering risk, which may relate to equity issuances or convertible debt instruments. The company's reliance on large capital expenditures to maintain competitive positioning in the CDMO space adds to the financial leverage risk.

Recent observations from investor relations indicate strong analyst sentiment, with a mean recommendation of 1.92 (closer to buy) and a mean price target of CHF 661.65, which is significantly higher than the current market price of CHF 10.33. This discrepancy suggests either a data anomaly in the price target or market price units, or a strong consensus on future value recovery. The high price targets (high of CHF 815.00) imply that analysts expect a substantial turnaround or re-rating of the company's earnings power.

Operating margin of 19.0% significantly exceeds the pharmaceutical cohort median of 6.0%, indicating superior operational efficiency.

Free cash flow turned positive to CHF 64 million in FY2026, reversing a multi-year trend of negative cash generation.

Analysts project substantial upside with a mean price target of CHF 661.65 versus the current market price of CHF 10.33.

Gross profit expanded to CHF 3.59 billion in FY2026, reflecting strong top-line pricing power and cost management.

Return on invested capital stands at 9.9%, demonstrating the company's ability to generate returns above its cost of capital.

Long-term debt surged to CHF 5.12 billion in FY2025, increasing financial leverage and potential interest burden.

Cash conversion ratio of -4.2 places the company in the bottom quartile of its pharmaceutical peer group.

The company faces medium-level liquidity, dilution, and credit risks, highlighting potential vulnerabilities in its financial structure.

Revenue CHF 6.53B, +19,2% YoY; Operating income +36,5% YoY.

• ▍Revenue CHF 6.53B, +19,2% YoY
• ▍Operating income +36,5% YoY
• ▍Net income −143,2% YoY
• ▍Free cash flow +114,1% YoY
• ▍Net margin -4.2%

Revenue CHF 5.48B, −18,4% YoY; Operating income +3,2% YoY.

• ▍Revenue CHF 5.48B, −18,4% YoY
• ▍Operating income +3,2% YoY
• ▍Net income −2,8% YoY
• ▍Free cash flow +32,0% YoY
• ▍Net margin 11.6%

Revenue CHF 6.72B, +7,9% YoY; Operating income −42,9% YoY.

• ▍Revenue CHF 6.72B, +7,9% YoY
• ▍Operating income −42,9% YoY
• ▍Net income −46,2% YoY
• ▍Free cash flow −136,2% YoY
• ▍Net margin 9.7%

Revenue CHF 6.22B, +15,1% YoY; Operating income +81,1% YoY.

• ▍Revenue CHF 6.22B, +15,1% YoY
• ▍Operating income +81,1% YoY
• ▍Net income −58,7% YoY
• ▍Free cash flow +22,7% YoY
• ▍Net margin 19.5%

Revenue CHF 5.41B; Operating income CHF 851.0M.

• ▍Revenue CHF 5.41B
• ▍Operating income CHF 851.0M
• ▍Net margin 54.4%